Anti-apoptotic genes, including those of the Bcl-2 family, have been shown to have dual functionality inasmuch as they inhibit cell death but also regulate inflammation. Several anti-apoptotic molecules have been associated with endothelial cell (EC) survival following transplantation; however, their exact role has yet to be elucidated in respect to controlling inflammation. In this study we created mice expressing murine A1 (Bfl-1), a Bcl-2 family member, under the control of the human intercellular adhesion molecule 2 (ICAM-2) promoter. Constitutive expression of A1 in murine vascular ECs conferred protection from cell death induced by the proinflammatory cytokine tumour necrosis factor (TNF)-a. Importantly, in a mouse model of heart allograft transplantation, expression of A1 in vascular endothelium increased survival in the absence of CD8 1 T cells.
Introduction
Endothelial cells (ECs) lining blood vessels function at the interface between the bloodstream and tissue. EC activation and death are believed to be key initiating events in the development of transplant vascular disease [1] . This idea is supported by the strong correlation between graft survival and expression of protective genes in vascular ECs. In animal models, where long-term allograft survival was established, expression of anti-apoptotic molecules A20, haem oxygenase-1 (HO-1), Bcl-xL and Bcl-2 were observed in graft ECs [2] [3] [4] [5] . Some of these molecules have a dual cytoprotective role, inasmuch as they inhibit cell death but also act as anti-inflammatory mediators. For example, A20 has been shown to inhibit nuclear factor kappa B (NF-jB) activation to a number of stimuli, including oxidative stress and inflammatory cytokines [6, 7] . Recently, overexpression of A20 in the vasculature, both ECs and smooth muscle cells (SMCs), using recombinant A20 adenovirus, reduced transplant arteriosclerosis in a mouse aorta to a carotid artery allograft model [8] . Protection correlated with decreased graft inflammation, with the infiltrating cells being predominantly regulatory T cells (T regs ), suggesting that maintaining the endothelium in a damage-free state may help to tip the balance towards transplant tolerance [8] .
A1, known as Bfl-1 in the human setting [9] , is another anti-apoptotic molecule with dual cytoprotective abilities [9] [10] [11] [12] [13] [14] . Unlike Bcl-2 and Bcl-xL, the expression of A1 is induced rapidly in ECs following stimuli from proinflammatory cytokines such as tumour necrosis factor (TNF)-a and interleukin (IL)21b [15] . NF-jB activation is required for the induction of A1 in ECs [10, 16] . Expression of A1, following retrovirus transduction, protected both human dermal microvascular endothelial cells (HMEC-1) and human umbilical vein endothelial cells (HUVEC) against TNF-a2induced apoptosis [15, 17, 18] . Induced expression of A1 not only inhibited ECs death but also their activation (reduction of E-selectin levels and IL-8 production), making this molecule a potential regulator of inflammation [10] . A1 may regulate inflammation in ECs by inhibiting NF-jB activation, given that expression of full-length A1 in bovine aortic ECs (BAEC) inhibited TNF-a-mediated I kappa Ba (IKBa) degradation and subsequently NF-jB activation [10, 16] .
Due to the anti-apoptotic and anti-inflammatory nature of A1, we investigated the role of this molecule in graft outcome when expressed constitutively in the vascular endothelium. To achieve this, we generated mice expressing the mouse A1 gene under the control of the human intercellular adhesion molecule 2 (ICAM-2) promoter [19] and assessed the role of this molecule in a vascular transplant setting. We observed that expression of A1 in ECs conferred protection in a murine heart transplant setting due to maintaining ECs in a non-inflammatory state [20, 21] .
Materials and methods
Animal studies were carried out in accordance with UK Research Councils and Medical Research Charities guidelines on responsibility in the use of animals in Bioscience Research, under a UK Home Office Licence (PPL70/7302). The anaesthesia used was isoflurane, euthanasia via CO 2 inhalation.
ICAM-2/A1 transgenic mice
The human ICAM-2 containing pBluescript II SK1 plasmid was kindly provided by Dr Peter Cowan (St Vincent's Hospital, Sydney, Australia), and the murine A1 cDNA containing pBluesK plasmid was kindly provided by Professor Michael B. Prystowskyt (Albert Einstein College of Medicine, New York, NY, USA). Murine A1 was excised from the plasmid using HindIII and BamH1 restriction digestion before being ligated into the EcoR1 cloning site of pBluescript II SK1 plasmid, upstream of the ICAM-2 promoter and the universal intron. A 1Á6 kb microinjection construct containing both the ICAM-2 promoter and A1 gene was excised from the vector by Xho1 and Not1 enzyme restriction digestion. The injection fragment (1Á6 Kb) was then separated by agarose gel electrophoresis, followed by purification through sequential Wizard mini columns (Promega, Madison, WI, USA) and CHROMA SPIN 400 (Clontech, Palo Alto, CA, USA). The purified fragment was microinjected at a concentration of 10 mg/ml in phosphate-buffered saline into fertilized CBA 3 C57BL6 mouse oocytes (Karolinska Institute, Stockholm, Sweden). Founder progeny were screened for transgene integrity by Southern blot analysis using the 32 Plabelled 1600 base pairs (bp) injection fragment as a probe. In addition, mice were screened using polymerase chain reaction (PCR) using ICAM-A1 forward primer (5 0 -TTTGCAGAAGGCTAGGGAT-3 0 ) and reverse primer (5 0 -TTCAACTTCCTTCTGAACGG-3 0 ). The resulting 356 bp product was resolved by electrophoresis in 1% agarose. Transgenic founders were bred onto a C57BL/6 (B6) background for more than 10 generations. Mice were kept under sterile conditions.
EC isolation and cell culture
Murine ECs were purified from murine heart tissue using a method described previously [22] . In brief, murine hearts were digested with collagenase (from Clostridium hostolyticum Type IV; Sigma Aldrich, St Louis, MO, USA) and trypsin (Invitrogen, Paisley, UK) to obtain a single-cell suspension. ECs were isolated following incubation with rat anti-CD31, anti-CD105 (BD Biosciences, San Jose, CA, USA) and biotinylated isolectin B4 (Vector Laboratories, Peterborough, UK)-specific antibodies and anti-rat immunoglobulin (Ig) and streptavidin-coupled bead selection, using MS columns (Miltenyi Biotech, Bergisch Gladbach, Germany). ECs were then cultured for 7-10 days in Dulbecco's modified Eagle's medium (DMEM) supplemented with 20% fetal calf serum (FCS) (GE Healthcare, Cardiff, UK), 2 mM glutamine and penicillin/streptomycin, 50 mM 2-mercaptoethanol, 1% non-essential amino acids, 1 mM sodium pyruvate, 20 mM Hepes (Invitrogen) and EC growth factors (Sigma Aldrich) at 378C/5% CO 2 . Once the cells had reached 90% confluence they were harvested using trypsin and replated. For functional assays, ECs were used between passages 3 and 4. ECs at 90% confluence were used for all experiments. To check that the cultured cells were indeed ECs, cells were harvested using Accutase (Invitrogen) and stained with anti-CD105-phycoerythrin (PE)-labelled antibodies before being analysed by flow cytometry (BD FACSCalibur; BD Biosciences). Subsequent analysis was accomplished with FlowJo software (TreeStar, Inc., Ashland, OR, USA). To test A1 mRNA expression in the cultured ECs, cells were lysed using Trizol and RNA extracted using an RNeasy mini kit (Qiagen, Valencia, CA, USA). A one-step reverse transcription-polymerase chain reaction (RT-PCR) kit (Promega) was used with the following primers 5 0 -AACTTCCACAAGAGCAGATTGCC-3 0 and 5 0 -TCAGCCAGCCAGATTTGGGTTC-3 0 to amplify A1 mRNA. 
Heart transplantation
Intra-abdominal heterotopic heart transplantation (either ICAM-2/A1 or non-transgenic grafts) was performed in CBA mice (Harlan Laboratories, Indianapolis, IN, USA), as described previously [23] . Heart allograft survival was assessed by direct abdominal palpation, where rejection was defined by complete cessation of cardiac impulses. Some mice were treated with 250 lg of anti-CD8 antibody, 1 day prior to and after transplantation, via intraperitoneal injection. Hearts were isolated on day 100, sectioned and stained with haematoxylin and eosin (H&E).
Measuring expression of adhesion molecules
ECs, 2Á5 3 10 4 , were grown to 90% confluence in six-well plates at 378C/5% CO 2 ; 10 ng/ml of TNF-a was added for 24 h. Cells were removed from the plate using Accutase before being incubated with Fc block (anti-CD16/32 antibody; Affymetrix eBioscience, Hatfield, UK) for 30 min at 48C. Cells were then stained with anti-ICAM-1 or antivascular cell adhesion protein 1 (VCAM-1) fluorescein isothiocyanate (FITC) antibodies or isotype controls (Affymetrix eBioscience) before being analysed by flow cytometry and FlowJo software.
Statistics
Statistical comparisons for experiments assessing in-vitro proliferation were performed using unpaired two-tailed Student's t-tests [24] . Mean survival time of heart allografts was assessed by log-rank test. Statistical significance is expressed as (*) and is defined as P-values lower than 0Á05.
Results

Constitutive expression of A1 in ECs prolongs the survival of transplanted hearts
As both anti-apoptotic molecules Bcl-2 and Bcl-xL have been implicated in protecting graft ECs during transplantation, we addressed whether the expression of A1 in ECs also has this capacity. To this end, we generated mice Plabelled injection fragment as a probe (b, top panel) and by PCR using specific primers (b, lower panel). ECs were isolated from the hearts of the ICAM-2/A1 and non-transgenic (NT) littermates and grown in vitro for 7 days before the expression levels of CD105 were assessed using specific conjugated antibodies and flow cytometry (c, upper panels). Histograms representing the expression of CD105 in ECs are shown compared to unstained or secondary antibody-stained ECs. Expression of A1 at the mRNA level was assessed using reverse transcription-polymerase chain reaction (RT-PCR) using two A1-specific primers and a control b actin primer (c, lower panels).
A1 expression in
expressing murine A1 in ECs (ICAM-2/A1 mice, Fig. 1a,  b) . We used the human ICAM-2 promoter to target A1 to ECs. This promoter has been shown previously to target human CD59 expression to the endothelium of all tissues [25, 26] due to the high expression of ICAM-2 on all vascular ECs, including those of the heart [27] . Indeed ECs, identified by their expression of CD105 [22] (Fig. 1c, top  panels) , isolated and expanded from the hearts of ICAM-2/ A1 mice, expressed A1 at the mRNA level (Fig. 1c, lower  panels) . In comparison, ECs isolated from non-transgenic mice did not, therefore confirming the expression of the A1 gene in ECs isolated from these transgenic mice.
To assess whether constitutive A1 protected the endothelium in vivo from immune-mediated damage elicited during transplantation, we transplanted hearts derived from ICAM-2/A1 mice (on a B6 background) or non-transgenic littermates into CBA/Ca recipients. We observed rapid rejection of donor hearts in recipient mice regardless of the expression of the A1 gene (mean survival time was days 6 and 7Á5 for non-transgenic and ICAM-2/A1 transgenic donor hearts, respectively, P 5 0Á08, Fig. 2a) . We have shown previously that treatment of recipient mice with anti-CD8 antibody, to remove the contribution of CD8
1 T cells to graft rejection, allowed prolongation of heart transplants in a complete mismatched transplant model [23] . In conjunction with anti-CD8 therapy treatment, given 1 day prior to and after heart transplantation, constitutive expression of A1 on ECs led to significant heart transplant survival compared to control hearts (mean survival time was 86 versus 17 days for ICAM-2/A1 hearts versus non-transgenic littermates, P < 0Á001 and Fig. 2b) . Overall, these observations suggest that expression of this anti-apoptotic gene did not protect ECs against direct CD8-mediated killing; however, when anti-CD8 antibody was used, A1 expression by the graft improved transplant outcome significantly.
Murine vascular ECs expressing A1 are less susceptible to cytokine-mediated activation
Given the transplant survival data, it was important to understand how constitutive expression of A1 contributes towards graft protection. The proinflammatory cytokine TNF-a has been shown to be an important mediator of allograft rejection [28] , with prolongation of allograft hearts survival being reported in recipient mice lacking the TNF receptor [29] . As over-expression of A1, using retrovirus transduction, protected human ECs against TNF-a-induced apoptosis [15] , we tested whether or not constitutive expression of A1 protected murine ECs from TNF-a-induced cell death. ECs isolated from the hearts of ICAM-2/A1 transgenic mice were treated with different concentrations of TNF-a (0Á01-100 ng/ml) in the presence of Act D (1 lg/ml) for 24 h. Cell viability was measured using an MTT assay. No significant EC death was evident in the presence of Act D (data not shown), and ECs treated with Act D only were deemed to be 100% viable. We observed that after 24 h of treatment with either 0Á01 or 0Á1 ng/ml of TNF-a, in combination with Act D, ECs isolated from ICAM-2/A1 transgenic mice were less susceptible to cytokine-induced cell death than ECs from non-transgenic mice (P-values were 0Á003 and 0Á023, respectively). However, treatment with higher doses, 1, 10 and 100 ng/ml TNF-a plus Act D, induced similar levels of cell death in ECs isolated from either ICAM-2/ A1 transgenic or non-transgenic mice (Fig. 3a) , suggesting that constitutive A1 expression in heart ECs provides protection from low levels of proinflammatory cytokines.
A1 expression may modulate immune recruitment
In addition, A1 has been described as a potential antiinflammatory molecule [10] . Therefore, it is feasible that constitutive expression of this molecule in the murine endothelium protects against both cell death and proinflammatory cytokine-mediated activation by inhibiting/ reducing expression of key inflammatory adhesion molecules required to recruit lymphocytes. In rat allografts, ICAM-1 and VCAM-1 expression are increased significantly on capillary endothelia, while only VCAM-1 expression was observed on arteries and arterioles during acute transplantation rejection [24] . As expression of both ICAM-1 and VCAM-1 on ECs are increased by proinflammatory cytokines such as TNF-a [30] [31] [32] [33] , we treated ECs isolated from the hearts of ICAM-2/A1 transgenic or nontransgenic littermates with TNF-a (10 ng/ml), and expression of the aforementioned molecules was assessed via flow cytometry. ECs isolated from both non-transgenic littermates and ICAM-2/A1 mice expressed ICAM-1 and VCAM-1 at low levels (data not shown). As expected, TNF-a induced expression of ICAM-1 and VCAM-1 on ECs isolated from non-transgenic mice by a two-to fivefold increase (Fig. 3b) . However, although not significant, reduced ICAM-1 and VCAM-1 expression was observed when A1 was expressed in ECs in all three experiments (Fig. 3b) . Next, to analyse whether this reduction in adhesion molecules expression led to an altered cell infiltration, cardiac grafts were harvested from mice receiving an ICAM-2/A1 heart or a non-transgenic heart day 100 post-transplantation, and tissue sections were stained with H&E. At this time-point the ICAM-2/A1 heart, but not the non-transgenic heart, was still palpitating. An intact heart structure, with little leucocyte infiltration, was observed in the A1-expressing heart and there was no evidence of cardiac allograft vasculopathy in coronary vessels. In contrast, diffuse myocardial inflammation with extensive myocyte damage, haemorrhage, fibrosis and vasculitis was seen in the non-transgenic heart (Fig. 3c , increased magnification shown in the insert box). To rule out that the diminished infiltration seen was due to A1-expressing dendritic cells (DCs) having a reduced capacity to activate T cells, antigen-specific CD4 and CD8 T cells were stimulated with antigen-pulsed DCs isolated from ICAM-2/A1 or non-transgenic mice and T cell proliferation was measured. DCs isolated from ICAM-2/A1 mice stimulated both CD4 and CD8 T cell responses to the same extent as DCs isolated from control mice (data not shown). In conclusion, constitutive expression of A1 may protect murine ECs from proinflammatory cytokine-mediated cell death and activation, both of which may have led to the prolonged allograft survival observed in vivo.
Discussion
During transplantation EC dysregulation is the key initiator of graft rejection, and inhibiting EC activation is an effective way to prevent graft loss. Over-expressing antiapoptotic genes such as HO and A20 in ECs protect ECs from cytokine-mediated activation and cell death [2, 3] . In addition, anti-apoptotic molecules are expressed in 'accepted' graft tissues [2] . In this study we extend these findings to Bfl-1/A1, a TNF-a-inducible anti-apoptotic molecule. In ECs under normal conditions, A1 is expressed either at low levels or not at all, but is induced via NF-jB activation in response to inflammatory stimuli. Overexpression of this molecule has been shown previously to inhibit ECs activation [10] , making it a promising antiinflammatory and cytoprotective molecule for these cells.
It has been reported that A1, like other Bcl-2 family members, is located in the mitochondria, where it binds to Bid and tBid to inhibit the activation of the pro-apoptotic Bcl-2 family members, Bak and Bax [12, 34] . A1 has four Bcl-2 homology (BH) domains in addition to a C-terminal domain containing an amphipathic tail. Expression of fulllength A1 by recombinant adenovirus (rAd) has been shown to protect human ECs from staurosporine [35] and TNFinduced cell death [15] . This may be due to both the BH4 and C-terminal domains of this molecule, both of which have been reported to be involved in the anti-apoptotic function of A1 [36] . Here, we show that constitutive expression of A1 can protect murine ECs from low levels of TNF-a in vitro. This proinflammatory cytokine has been shown to be an important mediator of allograft rejection [28] . In a rat cardiac transplant model, TNF-a protein levels within allografts were maximal 3 days post-transplant [37] . Whether A1 expression in the murine endothelium protects against this early in-vivo production of TNF-a is as yet unknown.
A1 has also been shown to inhibit NF-jB activation in ECs [10] , suggesting that this molecule could have an antiinflammatory function in ECs. Interestingly however, Guedes et al. [35] observed that when human HUVEC and HDMEC were transduced with recombinant adenovirus (rAd.) expressing full length human A1 (rAd.A1), TNFinduced up-regulation of ICAM-1 in ECs was not inhibited, reflecting a lack of inhibited of NF-jB activation, as measured by IKBa degradation. This result contradicted their earlier research on BAEC, where they expressed A1 via transfection with an A1 plasmid [18, 35] . However, expression of full-length A1, using rAd.A1, in bovine ECs gave the same result as in human cells with respect to IKBa degradation [35] . These authors concluded that full-length A1 does not inhibit NF-jB activation. However, they observed that expressing only the C-terminal domain of A1, using rAd., in human ECs led to an anti-inflammatory effect, as shown by a lack of ICAM-1 up-regulation in response to TNF-a [35] . They suggested that cleavage of A1 at the C-terminal domain may be important for its anti-inflammatory effect, possibly by releasing A1 from the mitochondria, given that the C-terminus is crucial for anchoring A1 to this organelle. We found that constitutive expression of full-length murine A1 in murine vascular ECs appears to reduce, although minimally and not statistically significantly, the induction of both ICAM-1 and VCAM-1 following TNF-a stimulation. In addition, reduced immune infiltration was observed in heart allografts expressing A1 in murine vascular ECs, suggesting perhaps a limited expression of adhesion molecules on these cells. Whether the difference between our study and that of Guedes et al. [35] reflects a difference in species used and type of EC studied (HUVEC and HDMEC versus murine vascular ECs) or a level of expression difference (rAd. transduction versus endogenous ICAM-2 promoterdriven expression) is unknown at present.
Given that A1 expression increased the mean survival time of transplanted murine hearts from 17 to 86 days, the assessment of whether expression of Bfl-1 in human vascular endothelium also confers protection is warranted. Viral vectors to target molecules to vascular endothelium are limited by their lack of specificity to only ECs. Several promoters have been used to target EC in vivo. Lei et al. [38] used adenoviral vectors containing an ICAM-2 promoter linked to lacZ, to transduced murine hearts ex vivo [38] . These authors found high lacZ expression (22-57%) in ECs of the coronary arteries and veins in four of 22 donor grafts 3 days following transduction with 10 10 plaque-forming unit virus [38] . Expression was ECs-specific, as no lacZ expression was observed in cardiomyocytes [38] . Given our data, we suggest that targeting anti-apoptotic molecules such as Bfl-1, perhaps through adenovirus infection to ECs, using the ICAM-2 promoter may be a promising targeting strategy for gene therapy. In conjunction with this, other therapies may also be required, as expression of A1 did not protect against direct pathway-activated CD8 1 T cells.
